Proudly Standing At The Leading Edge Of Urologic Cancer Care
Announcing the PIVOT-006 Clinical Trial
This trial offers hope to bladder cancer patients to prevent the recurrence of their disease following surgical tumor removal.
The need for a bladder cancer trial
Bladder cancer remains a significant health concern, especially for patients with
Intermediate-Risk (IR), Non-Muscle Invasive Bladder Cancer (NMIBC). Clinical sites like Urology Nevada play a crucial role in advancing medical research and improving outcomes for patients with NMIBC.
Up to 50% of people who have bladder cancer experience a recurrence within 12 months of transurethral resection of bladder tumor (TURBT). And 75% of high-risk bladder cancer patients will recur, progress, or die within 10 years.
Urology Nevada is committed to advancing bladder cancer research and improving patient outcomes to help change these devastating statistics.
About the PIVOT-006 clinical trial
PIVOT-006 (NCT06111235) is a phase 3 randomized clinical trial for the treatment of NMIBC. The purpose of this study is to see if cretostimogene grenadenorepvec, the study drug, can reduce the risk of bladder cancer returning or coming back as quickly. Patients and the study doctor will know if they are receiving cretostimogene.
Participants in the PIVOT-006 study will either receive surgical treatment plus cretostimogene or surgical treatment alone. The study is an open-label study, meaning both the doctor and the patient can know if they are receiving cretostimogene. Cretostimogene will be instilled into the bladder for a total of 14 times over a 12 months.
The Principal Investigator for the clinical trial is Dr. Dimitar Zlatev. Dr. Ross Anderson is the Sub-Investigator.
Who may be eligible to take part in this study
People with:
- Bladder cancer that has not invaded the muscle (Non-Muscle Invasive Bladder Cancer)
- Intermediate-Risk Disease
- 18 years or older